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Abstract
Stroke and liver cirrhosis are common in our everyday clinical practice, both of 
which can lead to serious complications. Their association is unclear. In this chapter, 
we briefly summarized the epidemiology of liver cirrhosis in stroke, reviewed the 
current evidence regarding the association between liver cirrhosis and stroke, and 
discussed the potential mechanisms for explaining such an association, such as 
coagulopathy, hypoperfusion, cardiac diseases, diabetes, and dyslipidemia.
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1. Introduction
Stroke and liver cirrhosis are two leading causes of death worldwide [1]. Patients 
with liver cirrhosis often have coagulopathy, hypoperfusion, cardiac diseases, 
diabetes, and dyslipidemia, which are associated with the development of stroke. 
Recent evidence also suggests a higher risk of stroke in liver cirrhosis. In the present 
chapter, we reviewed the current evidence regarding epidemiology of stroke in liver 
cirrhosis, association of stroke with liver cirrhosis, and their potential mechanisms.
2. Stroke
Stroke is the second leading cause of death and disability worldwide, which is 
defined as an acute episode of focal dysfunction of the brain, retina, or spinal cord 
[2]. It is often divided into hemorrhagic and ischemic stroke. Hemorrhagic and 
ischemic stroke leads to 2978 and 3348 thousands people dying until 2015, respec-
tively [1]. Over two thirds of stroke-related deaths occur in developing countries 
in the world [3], especially in low-income and middle-income countries [4]. 
Burden of stroke in Asia is heavier than Europe or North America [5]. Patients with 
stroke are more susceptible to suffer systemic complications, including cardiac, 
pulmonary, gastrointestinal, genitourinary, musculoskeletal, and neuropsychiatric 
systems, venous thromboembolism, and so on [6, 7]. Prognosis of stroke is poor. 
About 20–30% of patients died 6 months after stroke, 20–30% had moderate to 
severe disability, and 20–25% had mild to moderate disability [8]. Traditional risk 
factors of stroke are hypertension, decreased physical activity, increased ratio of 
lipoprotein (Apo)B/ApoA1 and waist-to-hip, unhealthy diet, depression status, 
smoking, cardiac disease, alcohol intake, and diabetes mellitus [4, 9]. Additionally, 
our clinical practice suggested that acute upper gastrointestinal bleeding would lead 
to stroke [10]. Several possible explanations are as follows. First, massive blood loss 
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Figure 1. 
The association between liver cirrhosis and hemorrhagic stroke.
leads to reduced blood supply to the brain secondary to cerebral vessel vasoconstric-
tion. Second, massive blood loss sometimes leads to reactive thrombocytosis [11], 
thereby resulting in potential hypercoagulability. Third, hemocoagulase is occasion-
ally employed for the treatment of gastrointestinal bleeding, which could reduce 
fibrinogen concentration [12]. Fourth, blood transfusion is an important treatment 
of upper gastrointestinal bleeding [13], but the ischemia reperfusion injury of brain 
cannot be ignored.
3. Liver cirrhosis
Liver cirrhosis is an end stage of liver disease [14]. Histologically, it is character-
ized by diffuse fibrosis within hepatic tissue, false lobular formation, and regenera-
tive nodules [14, 15]. It is the 17th cause of death globally [16], and the mortality has 
increased steadily over the past 30 years, especially in Central Asia, North Africa, 
and the Middle East [17]. The major causes of liver cirrhosis are chronic hepatitis B 
virus (HBV) and hepatitis C virus (HCV) infection, alcoholism, nonalcoholic ste-
atohepatitis (NASH), drug abuse, and cholestasis [18–20]. The major complications 
are variceal hemorrhage [21], ascites [22], cirrhotic cardiomyopathy [23], hepatic 
encephalopathy [24], hepatocellular carcinoma [25, 26], portal vein thrombosis 
[27], and other common venous thromboembolism [28]. Up-to-date concept sug-
gests a tendency towards both bleeding and thrombotic events in cirrhotic patients 
due to decreased levels of both procoagulant and anticoagulant factors [29, 30].
4. Association between stroke and liver cirrhosis
Overall, it remains unclear about whether liver cirrhosis increases or reduces the 
risk of ischemic stroke. A majority of studies [31–35] indicated an obviously higher 
risk of overall, ischemic, and/or hemorrhagic stroke after adjusting the covariates 
in cirrhotic patients than non-cirrhotic patients. By contrast, another two studies 
by Chen [36] and Solaymani-Dodaran [37] suggested the protective role of liver cir-
rhosis in the development of ischemic stroke. Heterogeneous results regarding this 
association among the studies might be attributed to the selection of patients. The 
characteristics of study population were different. Studies by Chen and Solaymani-
Dodaran et al. focused on patients with nonalcoholic cirrhosis and primary biliary 
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cirrhosis, respectively. By comparison, the study population had unspecified liver 
cirrhosis in other studies. The association between liver cirrhosis and stroke was 
outlined according to the evidence from abovementioned studies (Figures 1 and 2 ).
5. Incidence/prevalence of stroke in liver cirrhosis
Regardless of the type of stroke, the prevalence of stroke was from 2.06 to 
53.81% [36–49] (Figure 3). Several subgroup populations should be further 
reported.
First, the prevalence of hemorrhagic stroke in liver cirrhosis seemed to be higher 
than that of ischemic stroke. The prevalence of hemorrhagic stroke was from 0.80 
to 34.33% [34–36, 50–56] (Figure 4).
The prevalence of ischemic stroke was from 0.85 to 6.55% [34, 36, 57, 58] 
(Figure 5).
Second, the annual incidence of ischemic stroke in cirrhotic patients with atrial 
fibrillation was 1.2% [59]. The prevalence of stroke in cirrhotic patients with atrial 
fibrillation was 53.81 and 34.58% in the studies by Kuo [38] and Lee [44], respec-
tively. This figure is significantly higher than that reported by studies including 
unclassified cirrhotic patients without atrial fibrillation.
Figure 2. 
The association between liver cirrhosis and ischemic stroke.
Figure 3. 
The prevalence of stroke in liver cirrhosis.
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Figure 5. 
The prevalence of ischemic stroke in liver cirrhosis.
Third, the annual incidence of aneurysmal subarachnoid hemorrhage (SAH) in 
cirrhotic patients was 0.11% [31].
6.  Potential mechanisms for the association between stroke and liver 
cirrhosis
There are several potential mechanisms for explaining the association between 
stroke and liver cirrhosis.
6.1 Coagulopathy
Coagulation and anticoagulation factors maintain a dynamic balance to prevent 
from the development of thrombosis and hemorrhage in healthy population [60]. 
By comparison, coagulopathy is frequently observed in cirrhotic patients [61] 
due to an imbalance between coagulation and anticoagulation factors [62]. First, 
clotting factors are often decreased in cirrhotic patients [63] and in parallel to the 
Figure 4. 
The prevalence of hemorrhagic stroke in liver cirrhosis.
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progression of liver disease [64]. Second, the mean lifetime of platelet is shortened 
and thrombopoietin production is decreased [65]. Thrombocytopenia is also caused 
by hypersplenism, antiplatelet autoantibodies, toxic effects of excessive alcohol 
intake, and treatment with interferon [65, 66]. Third, a hypercoagulable status has 
been recognized in advanced cirrhosis due to increased levels of factor VIII and 
decreased levels of protein C [64]. Therefore, both hemorrhage and thrombosis can 
develop in cirrhotic patients.
6.2 Hypoperfusion
Hypoperfusion is often observed in liver cirrhosis. First, ascites is a common 
clinical sign in cirrhotic patients due to liver dysfunction and portal hypertension 
[67], in which lots of capillary fluids leak into abdominal cavity. Second, serum 
albumin level is often decreased in liver cirrhosis, which can decrease intravascular 
osmotic pressure [68]. Third, massive gastrointestinal bleeding secondary to gastro-
esophageal variceal rupture is a common complication of liver cirrhosis, leading to 
the hypoperfusion of various organs [21]. Fourth, there is a hyperdynamic circula-
tion status in cirrhotic patients, which is characterized by arterial hypotension, high 
cardiac output, and low peripheral vascular resistance [69, 70].
6.3 Cardiac diseases
Cirrhotic patients often present with cirrhotic cardiomyopathy defined as 
cardiac systolic and/or diastolic dysfunction in the absence of previous history of 
heart disease [23]. Additionally, cardiac arrhythmias, especially atrial fibrillation, 
have been increasingly recognized in patients with chronic liver diseases [71, 72]. A 
nationwide population-based study suggests an increased risk of atrial fibrillation 
development in cirrhosis [73].
6.4 Diabetes
Up to 70% of cirrhotic patients develop diabetes or impaired glucose tolerance 
[74]. Evidence also suggests an association of hepatogeneous diabetes with higher 
portal pressure and increased risk of hepatocellular carcinoma, hepatic encepha-
lopathy, and mortality in cirrhosis [75]. Several potential mechanisms of hepatoge-
neous diabetes include [1] reduced insulin clearance and hyperinsulinemia [76], [2] 
beta cell failure and reduced insulin secretion [77], and [3] increased secretion from 
alpha cells and hyperglucagonemia [75].
6.5 Dyslipidemia
Liver plays a key role in the synthesis, decomposition, and digestion of lipids, 
and dyslipidemia is found in patients with impaired liver function. Triglycerides, 
the ratio of triglycerides to high-density lipoprotein, and the ratio of apolipoprotein 
B to apolipoprotein A1 increase in cirrhotic patients [78, 79].
7. Conclusions
Patients with liver cirrhosis might have an increased risk of stroke probably 
due to their concomitant high-risk factors, such as coagulopathy, hypoperfusion, 
cardiac diseases, diabetes, and dyslipidemia. Once a patient was diagnosed with 
liver cirrhosis, the management of stroke should be initiated.
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